Investing in the Development & Conservation of New Antibiotic Treatments

Peter Beyer, WHO & Jean-Pierre Paccaud, DNDi

13 November 2015

New models for R&D: The Global Antibiotic R&D Partnership

Michelle Childs
How it works:

With Public and Private Funding

Conducts research with:

- Biotechnology & Pharmaceutical Industries
- Universities
- Public Research Institutions
- Ministries of Health

For neglected patients

To develop and deliver treatments
GARDP: Vision:
In cooperation with the public and private sectors:
• develop new antibiotic treatments addressing AMR
• promote their responsible use for sustainable access
by setting up a not-for-profit product development partnership that will focus on global health needs, and ensuring any new product is adapted to resource-limited settings.

2014
- DNDi consultations
- Business Plan scope – AMR suggested
- 8-9 Dec. 2014 WHO-DNDi meeting to explore PDP for antibiotics

2015
- May 2015 WHA adopts GAP-AMR + resolution
- Oct. 2015 G7 Declaration: explore PDP for AMR

2016
- 13 Nov. 2015 DNDi-WHO consultation support for PDP
- 1 Dec. 2015 Board approves incubation
- 29 Feb. 2016 1st Scientific consultation Institut Pasteur
- 24 May 2016 GARD Launch

EUR 2.5 million of the required EUR 3 million seed funding committed to date:
Next steps: build a project portfolio with member states and key partners

**Short-term incubation goals:**
- with WHO, determine disease priorities, up to level of TPPs
- key partnerships in place
- governance structure
- two projects end 2016, two more by end 2017 that link incentives to conservation

**Potential projects in the short-term:**
- Disease specific: e.g. neonatal sepsis, gonorrhea, typhoid – others to be explored
- Transversal: e.g. platform for combinations and improving usage and understanding of old antibiotics; antibiotic memory recovery initiative

**Longer-term projects**
- Determine upstream ‘blue sky’ research opportunities
Thank you!